Axa’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Axa’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-51,597	Closed	-$5.54M	–	1193
2023 Q1	$5.54M	Buy	51,597 +284	+0.6%	+$32.7K	0.02%	537
2022 Q4	$5.64M	Buy	+51,313	New	+$3.33M	0.02%	564

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Axa's RXDX Position: Q2 2023 in Review

Axa sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 51,597 shares — an estimated $5.54M sold.

Axa first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $5.64M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Axa reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Axa sold 51,597 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.54M.
Axa first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Axa's Prometheus Biosciences, Inc. Common Stock position peaked at $5.64M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.